Research & Development
Publications & Presentations
Disclaimer
Etripamil is an investigational new drug which is not approved for commercial distribution in the United States. The publications in this section are for educational purposes to discuss clinical data relating to the investigational new drug. Etripamil has not been shown to be safe and effective for FDA approval purposes.
Phase 3
Randomized Controlled Trial – Secondary Outcomes
Self-Administered Etripamil and Emergency Department Visits in Supraventricular Tachycardia: A Secondary Analysis of a Randomized Clinical Trial
JAMA Cardiology (April 2025)
Randomized Controlled Trial – Secondary Outcomes
Self-Administered Etripamil Nasal Spray Relieved Symptoms, Decreased Heart Rate, and Reduced Medical Interventions During Atrioventricular Nodal–Dependent Paroxysmal Supraventricular Tachycardia
Circulation: Arrhythmia and Electrophysiology (Nov 2024)
Randomized Controlled Trial
First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301)
American Heart Association (Dec 2022)
Randomized Controlled Trial
Rationale For and Design of a Multicenter, Placebo-controlled, Phase 3 Study to Assess Efficacy and Safety of Intranasal Etripamil for the Conversion of Paroxysmal Supraventricular Tachycardia
American Heart Journal (Jun 2022)
Open-label clinical studies
Etripamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion: Results from the NODE-303 Open-label Study – ScienceDirect
The Journal of The American College of Cardiology (Mar 2024)
Open-label clinical studies
Rationale and design of the NODE-303 study: evaluating the safety of symptom-prompted, self-administered etripamil for paroxysmal supraventricular tachycardia episodes in real-world settings
American Heart Journal (Jan 2024)
Open-label clinical studies
Etripamil Nasal Spray for Conversion of Repeated Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia During Long‐Term Follow‐Up: Results From the NODE‐302 Study
Journal of the American Heart Association (Sep 2023)
Phase 2
Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm. Journal of the American College of Cardiology. 2018.
Journal of the American College of Cardiology (Apr 2018)
Pharmacokinetics/Pharmacodynamics
Cardiovascular and Pharmacokinetic Profiles of Intravenous Etripamil in Conscious Telemetered Cynomolgus Monkeys
International Journal of Toxicology (April 2025)
Pharmacokinetics and Pharmacodynamics of Etripamil, an Intranasally Administered, Fast‐Acting, Nondihydropyridine Calcium Channel Blocker (wiley.com).
Clinical Pharmacology in Drug Development. (Feb 2024)
Preclinical Safety Evaluation of Etripamil Nasal Spray in Cynomolgus Macaques (Macaca fascicularis) to Assess for Safety in Patients With Paroxysmal Supraventricular Tachycardia.
International Journal of Toxicology (July 2024)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intranasal Etripamil in Healthy Japanese and Non-Japanese Adults
Journal of the American College of Cardiology (jacc.org) (Mar 2022)
Health Economics and Outcomes Research/Real World Evidence
Catheter ablation for supraventricular tachycardia and health resource utilization and expenditures: A propensity-matched cohort study – ScienceDirect
International Journal of Cardiology (May 2024)
Prevalence and Incidence of Patients with Paroxysmal Supraventricular Tachycardia inthe United States.
Journal of Cardiovascular Electrophysiology (Aug 2021)
Disparities in the Management of Newly Diagnosed Paroxysmal Supraventricular Tachycardia for Women Versus Men in the United States. Journal of the American Heart Association. 2020.
Journal of the American Heart Association (Sep 2020)
Healthcare Resource Use and Expenditures in Patients Newly Diagnosed with Paroxysmal Supraventricular Tachycardia. American Journal of Cardiology. 2020.
American Journal of Cardiology. (Jan 2020)
Treatment Satisfaction and Relief of Symptoms with Self-administered Etripamil Nasal Spray: An Analysis of Phase 3 Randomized Trials
Heart Rhythm Society (April 2025)
Consistency and Predictiveness of Conversion Among Multiple Episodes of Paroxysmal Supraventricular Tachycardia (PSVT) Treated With Etripamil: Outcomes From the NODE-303 Trial
American College of Cardiology (March 2025)
Healthcare Resource Utilization (HRU) Among Patients with Paroxysmal Supraventricular Tachycardia (PSVT)
AMCP Nexus 2024 (October 2024)
Healthcare Resource Utilization After Etripamil Treatment to Terminate Paroxysmal Supraventricular Tachycardia: A Pooled Analysis of Clinical Trials
American College of Emergency Physicians (October 2024)
Assessing the Real-World Impact of Paroxysmal Supraventricular Tachycardia on Quality of Life: A Longitudinal Study with a Focus on Anxiety Burden.
Preventative Cardiovascular Nurses Association. (April 2024)
NODE 303: Multi-Center, Multi-National, Open-Label, Safety Study of Etripamil Nasal Spray for Patients with Paroxysmal Supraventricular Tachycardia.
American College of Cardiology (2024)
Self-administered Etripamil for Termination of Spontaneous Paroxysmal Supraventricular Tachycardia: Primary Analysis from the RAPID Study
American Heart Association (Nov 2022)
HRS 22: Long-Term Outcomes of the NODE-302 Study | Dr James Ip
Heart Rhythm Society (May 2022)
Etripamil Nasal Spray for Acute Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia
Heart Rhythm Society (May 2022)
Analysis of Clinical Outcomes in the NODE-301 Trial
American College of Cardiology (Apr 2022)
Very Low Efficacy of Vagal Maneuvers in Terminating Paroxysmal Supraventricular Tachycardia: Results From the NODE-301 Study
Heart Rhythm Society (Apr 2022)
Etripamil Nasal Spray Reduces Heart Rate in Patients with Paroxysmal Supraventricular Tachycardia Prior to Conversion to Sinus Rhythm
American Heart Association (Nov 2021)
.png){kind=small}